Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-05 09:35 • The Motley Fool Positive Axe Cap view: Selective

Upstart (UPST) has declined over 70% from its July peak and reached a new 52-week low, driven by investor worry rather than poor fundamentals. Despite the stock weakness, the company shows strong operational performance with Q2 revenue up 42% year-over-year and full-year guidance 40% above 2025 results. Analysts maintain a consensus price target of $39.24, suggesting 70% upside potential once market sentiment improves.

Axe note: Upstart’s steep decline masks solid revenue growth but carries risks amid tricky market sentiment.

2026-10-05 09:19 • The Motley Fool Negative Axe Cap view: Bearish

While SpaceX has transformational potential through Starlink and orbital compute services, analyst Adam Levy argues the stock is overvalued at current prices. He contends the market is pricing in Elon Musk's $1 trillion 2030 revenue projection as certainty rather than possibility. Levy identifies significant risks including massive capital requirements ($672 billion through 2034), regulatory challenges, and unproven technology. He values the stock at $78 per share based on a more conservative $300 billion revenue projection for 2030, compared to the current price of ~$159.

Axe note: SpaceX’s transformative potential is clear, but current valuations ask too much for too little certainty.

2026-10-05 08:26 • The Motley Fool Positive Axe Cap view: Selective

Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.

Axe note: Wall Street analysts see substantial upside in Argenx’s stock, driven by solid biotech growth, yet key risks remain.